| First Author | Marazioti A | Year | 2018 |
| Journal | Nat Commun | Volume | 9 |
| Issue | 1 | Pages | 672 |
| PubMed ID | 29445180 | Mgi Jnum | J:257943 |
| Mgi Id | MGI:6119207 | Doi | 10.1038/s41467-018-03051-z |
| Citation | Marazioti A, et al. (2018) Myeloid-derived interleukin-1beta drives oncogenic KRAS-NF-kappaBeta addiction in malignant pleural effusion. Nat Commun 9(1):672 |
| abstractText | Malignant pleural effusion (MPE) is a frequent metastatic manifestation of human cancers. While we previously identified KRAS mutations as molecular culprits of MPE formation, the underlying mechanism remained unknown. Here, we determine that non-canonical IKKalpha-RelB pathway activation of KRAS-mutant tumor cells mediates MPE development and this is fueled by host-provided interleukin IL-1beta. Indeed, IKKalpha is required for the MPE-competence of KRAS-mutant tumor cells by activating non-canonical NF-kappaB signaling. IL-1beta fuels addiction of mutant KRAS to IKKalpha resulting in increased CXCL1 secretion that fosters MPE-associated inflammation. Importantly, IL-1beta-mediated NF-kappaB induction in KRAS-mutant tumor cells, as well as their resulting MPE-competence, can only be blocked by co-inhibition of both KRAS and IKKalpha, a strategy that overcomes drug resistance to individual treatments. Hence we show that mutant KRAS facilitates IKKalpha-mediated responsiveness of tumor cells to host IL-1beta, thereby establishing a host-to-tumor signaling circuit that culminates in inflammatory MPE development and drug resistance. |
